Piramal Pharma Limited

BSE: 543635
Piramal Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24297MH2020PLC338592 Incorporated 04 March 2020 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 543635 Public Limited Company pharma
Data last updated
Market Cap
₹26,696 Cr
PPLPHARMA · NSE
Share Price
₹203.01
+1.24% today
Revenue
₹8,869 Cr
FY 2025-26 · -3.1% YoY
EBITDA
₹704 Cr
Margin 7.9%
Net Profit
−₹312 Cr
FY 2025-26 · -451.5% YoY
ROE
-3.8%
ROCE 2.5%
Debt / Equity
0.65
Interest cover -267.9x
Authorised capital
₹3,000 Cr
Registered with MCA

About Piramal Pharma Limited

Data last updated:

Piramal Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 March 2020 and has been in existence for over 6 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24297MH2020PLC338592. Its GSTIN is 27AALCP0909M1Z1 (Maharashtra). The company holds 19 GST registrations, all of them active. Its shares are listed on BSE: 543635.

The company has an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹1,331.35 Cr. It is led by directors including Peter D Deyoung (Whole-Time Director) and Nandini Ajay Piramal (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ananta Building Piramal Corporate Park, Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹8,869.08 Cr, a decline of 3.1% compared to the previous year. For the same year it recorded a net loss of ₹312.22 Cr (net margin -3.5%) and EBITDA of ₹704.05 Cr (EBITDA margin 7.9%). The net worth stands at ₹8,162.62 Cr (up 0.5% YoY). Total assets are valued at ₹14,088 Cr (up 6.7% YoY).

The company has about 3,851 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 4 brands: Piramal Pharma Solutions, Piramal Realty, Piramal Pharma and Piramal Group. As per MCA filings, the company has open charges of ₹2,430 Cr and satisfied charges of ₹1,000 Cr on record. Court records list 55 cases involving the company, including 41 filed by the company and 10 filed against it; 32 cases are pending. The company has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025. Its 10 peer companies in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Dow Chemical International Private Limited with revenue of ₹10,135 Cr. The company has 11 MSME Form 1 returns on record between 2021 and 2024, listing 326 overdue payments to 94 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website piramal.com.

Company Details of Piramal Pharma Limited
CIN L24297MH2020PLC338592
Registration Number 338592
Incorporation Date 04 March 2020
ROC Mumbai
Listing Status Listed (BSE: 543635)
Company Status Active
Date of Last AGM 30 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Peter D Deyoung Whole-Time Director Nandini Ajay Piramal Whole-Time Director Vivek Valsaraj Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    piramal.com
  • Social Media
  • Registered Address
    Ananta Building Piramal Corporate Park, Opp. Fire Brigade Kamani Junction Lbs Marg Kurla (West), Mumbai, Maharashtra, India – 400070
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Piramal Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Piramal Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Piramal Pharma Limited in one report.

Financials from FY 2020 Directors & ownership Charges & compliance

Business Activity of Piramal Pharma Limited

The main business activity of Piramal Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Piramal Pharma Limited FY 2025-26 filings available

Piramal Pharma Limited reported revenue of ₹8,869.08 Cr (down 3.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Profit before tax(176)415179(120)485949
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Balance sheet
Total assets14,08813,20612,82212,61210,9918,780
Net worth8,1638,1257,9116,7746,6975,605
Total debt5,6754,8564,7105,6374,1283,025
Cash & bank1,224501483308329406
Net working capital3,5413,5543,0592,7172,4031,751
Cash flow
Cash from operations1,6538921,005484766598
Cash from investing(820)(488)(416)(1,334)(1,737)(4,464)
Cash from financing(38.98)(441)(422)8187943,977
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Profit before tax877911508124462687
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
Balance sheet
Total assets9,0228,7447,9216,9366,3004,281
Net worth8,1417,4536,7125,2625,1234,101
Total debt7861,2431,1771,6491,164174
Cash & bank57417824264.16137152
Net working capital1,8422,1011,7971,3371,166463
Cash flow
Cash from operations1,32854935871.5224934.72
Cash from investing(318)(552)(635)(435)(1,165)(4,383)
Cash from financing(615)(61.74)4512908964,494
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
Other income292208235279335230
Total expenses8,1657,7067,0386,4605,6254,887
Employee cost2,4162,3072,0301,8961,5891,468
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Depreciation831816741677586545
Interest341422448344198163
Profit before tax(176)415179(120)485949
Tax15032416166.31109114
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8356,8016,5885,5805,5114,610
Shareholders' funds (net worth)8,1638,1257,9116,7746,6975,605
Minority interest0.000.000.000.000.000.00
Secured loans5,4704,5904,5365,4973,9812,601
Unsecured loans204266174140146424
Total debt5,6754,8564,7105,6374,1283,025
Total liabilities14,08813,20612,82212,61210,9918,780
Assets
Gross block14,82913,07712,09910,8429,5108,153
Net block8,6848,1337,9907,4696,8796,105
Capital work in progress1,1009771,1161,4191,172627
Investments437291385639267123
Inventories3,0642,3132,1761,6811,3891,232
Sundry debtors2,1582,3502,1341,7991,7851,575
Cash & bank balances1,224501483308329406
Loans & advances614614527620514436
Total current assets7,0605,7775,3204,4084,0173,649
Total current liabilities3,5192,2232,2611,6911,6141,898
Net working capital3,5413,5543,0592,7172,4031,751
Total assets14,08813,20612,82212,61210,9918,780
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18221953.2385.18262152
Net cash from operating activities1,6538921,005484766598
Net cash from investing activities(820)(488)(416)(1,334)(1,737)(4,464)
Net cash from financing activities(38.98)(441)(422)8187943,977
Net change in cash794(36.87)166(31.95)(177)110
Closing cash1,224501483308329406
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA growth-51.3%+27.5%+82.4%-33.5%-34.6%-
PBT growth-+131.3%+9998.0%--48.9%+9997.0%
Net income growth-451.5%+461.1%+108.5%-148.4%-53.0%-
Revenue CAGR (3Y)+7.8%+11.7%+9.0%---
EBITDA CAGR (3Y)+4.3%+15.6%-7.4%---
Profitability & leverage
Net income margin-3.7%+1.0%+0.2%-2.6%+5.7%+13.2%
Return on capital employed+2.5%+6.4%+5.4%+1.9%+6.9%+12.7%
Return on net worth-3.8%+1.1%+0.2%-2.8%+6.1%+14.9%
Debt / equity0.650.600.700.720.580.54
Long-term debt / equity0.480.370.410.460.420.43
Interest cover-267.9567.08114.15-621.1556.9018.51
Efficiency & per share
Fixed asset turnover0.640.730.710.700.740.77
Inventory turnover3.304.084.244.615.015.13
Debtors turnover3.944.084.153.953.904.01
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.5061.3559.8056.7656.4756.35
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
Other income663207202341225216
Total expenses4,2334,2453,7723,3532,8802,320
Employee cost745736614548448395
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Depreciation256222205192165144
Interest79.9511510711657.294.71
Profit before tax877911508124462687
Tax17722011654.1994.79115
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8146,1285,3894,0683,9373,106
Shareholders' funds (net worth)8,1417,4536,7125,2625,1234,101
Secured loans4211,0098961,3131,15490.20
Unsecured loans36523428133610.6984.06
Total debt7861,2431,1771,6491,164174
Total liabilities9,0228,7447,9216,9366,3004,281
Assets
Gross block4,5754,2493,7673,5653,2252,260
Net block3,0362,8942,6122,6022,4391,627
Capital work in progress221327533417405121
Investments3,5803,1051,7081,7471,6301,592
Inventories1,8731,2051,153819536421
Sundry debtors1,4061,6671,331910989840
Cash & bank balances57417824264.16137152
Loans & advances451486504456403355
Total current assets4,3053,5363,2302,2492,0651,768
Total current liabilities2,4621,4341,4339128991,305
Net working capital1,8422,1011,7971,3371,166463
Total assets9,0228,7447,9216,9366,3004,281
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16422954.281281470.74
Net cash from operating activities1,32854935871.5224934.72
Net cash from investing activities(318)(552)(635)(435)(1,165)(4,383)
Net cash from financing activities(615)(61.74)4512908964,494
Net change in cash395(64.93)175(73.41)(19.03)146
Closing cash57417824264.16137152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA growth-47.2%+68.4%+582.3%-80.3%-25.7%-
PBT growth-3.8%+79.5%+310.4%-73.3%-32.7%+9997.0%
Net income growth+11.4%+77.6%+434.0%-80.8%-32.0%-
Revenue CAGR (3Y)+11.6%+16.5%+14.3%---
EBITDA CAGR (3Y)+82.4%+31.3%-0.1%---
Profitability & leverage
Net income margin+14.6%+13.1%+8.9%+2.0%+11.0%+19.5%
Return on capital employed+10.8%+12.3%+8.3%+3.6%+9.8%+16.2%
Return on net worth+9.0%+9.8%+6.5%+1.3%+8.0%+13.9%
Debt / equity0.130.170.240.270.150.04
Long-term debt / equity0.050.050.080.110.050.00
Interest cover27.1914.0025.95-114.1519.430.99
Efficiency & per share
Fixed asset turnover1.081.321.201.011.221.30
Inventory turnover3.114.484.455.096.996.98
Debtors turnover3.113.533.923.633.653.50
EPS (₹)5.275.222.960.583.105.75
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.3456.2750.7444.0943.2041.23
Want more history and ratios?
You're viewing the latest exchange-filed financials for Piramal Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Peer Comparison of Piramal Pharma Limited

Piramal Pharma Limited is compared with the companies closest to it by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products). Its own revenue is ₹8,869.08 Cr.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Dow Chemical International Private Limited₹10,135 Cr••••••••••••1,228Thane, Maharashtra, India
Reckitt Benckiser (India) Private Limited₹9,882.29 Cr••••••••••••2,485Gurgaon, Haryana, India
Gujarat State Fertilizers & Chemicals Limited Listed₹9,848.64 Cr••••••••••••2,440Vadodara, Gujarat, India
Divi's Laboratories Limited Listed₹9,712 Cr••••••••••••11,845Hyderabad, Telangana, India
Macleods Pharmaceuticals Ltd₹9,671.68 Cr••••••••••••22,944Mumbai, Maharashtra, India
Procter & Gamble Home Products Private Limited₹9,228.83 Cr••••••••••••290Mumbai, Maharashtra, India
India Glycols Limited Listed₹9,053.5 Cr••••••••••••358Udham Singh Nagar, Uttarakhand, India
Ipca Laboratories Limited Listed₹9,032.39 Cr••••••••••••-Kandivali West, Maharashtra, India
Piramal Pharma Limited this company₹8,869.08 Cr••••••••••••-Mumbai, Maharashtra, India
Abbott Healthcare Private Limited₹8,811.32 Cr••••••••••••836Mumbai, Maharashtra, India
Deccan Fine Chemicals (India) Private Limited₹8,738.51 Cr••••••••••••3,496Hyderabad, Telangana, India

Peers are the five companies nearest above and the five nearest below Piramal Pharma by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company. Net profit, margin and growth of each peer are in the company report.

Auditor Details of Piramal Pharma Limited

Piramal Pharma Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023.

NameStatusAppointment DateCessation Date
Deloitte Haskins & Sells LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Piramal Pharma Limited

Piramal Pharma has 10 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Peter D DeyoungWhole-Time Director04 Mar 20206 Years 7 MonthsCurrent
Ramadorai Subramanian
Also directs: DSP Asset Managers Private Limited, British Asian India Foundation, Karmayogi Bharat and 3 more
Director09 Feb 20215 Years 7 MonthsCurrent
Jairaj Manohar Purandare
Also directs: J M Purandare & Co LLP, Cie Automotive India Limited, HDFC Asset Management Company Limited and 3 more
Director09 Feb 20215 Years 7 MonthsCurrent
Sridhar Gorthi
Also directs: Snark Capital Advisors LLP, Kshna Capital Advisors LLP, Vesuvius India Ltd and 3 more
Director30 Mar 20224 Years 6 MonthsCurrent
Nandini Ajay Piramal
Also directs: Montane Ventures Private Limited, Piramal Water Private Limited, Piramal Udgam Data Management Solutions
Whole-Time Director04 Mar 20206 Years 7 MonthsCurrent
Vivek Valsaraj
Also directs: Abbvie Therapeutics India Private Limited
Whole-Time Director09 Feb 20224 Years 7 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Shareholding Pattern of Piramal Pharma Limited

Shareholding for the quarter ended Sep 2026: promoters hold 34.80%, foreign institutional investors hold 12.50%, domestic institutional investors hold 14.60% and retail and other public shareholders hold 38.10%.

Promoters: 34.80%DII (Domestic Institutional): 14.60%FII (Foreign Institutional): 12.50%Retail & Others: 38.10%
Sep 2026
QUARTER
34.80% Promoters
14.60% DII (Domestic Institutional)
12.50% FII (Foreign Institutional)
38.10% Retail & Others
Promoter holding - history
Now 34.80% · Sep 2026High 34.90% · Dec 2025Low 34.80% · Sep 2026
33%33.8%34.5%35.3%36%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 34.90%Mar 2026: 34.90%Jun 2026: 34.90%Sep 2026: 34.80%34.90%34.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters34.80%34.90%34.90%34.90%
Public65.20%65.10%65.10%65.10%

Charges & Borrowings of Piramal Pharma Limited

Open charges
₹2,430 Cr
Satisfied charges
₹1,000 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹1,580.00 Cr
Others₹450.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹300.00 Cr
Standard Chartered Bank₹50.00 Cr
Citi Bank N.A.₹50.00 Cr
Latest charge details
DateLenderAmountStatus
19 May 2025Idbi Trusteeship Services Limited₹300 CrOpen
12 Dec 2024Idbi Trusteeship Services Limited₹100 CrOpen
10 Dec 2024Idbi Trusteeship Services Limited₹200 CrOpen
10 Dec 2024Idbi Trusteeship Services Limited₹100 CrOpen
10 Sep 2024Idbi Trusteeship Services Limited₹150 CrOpen

Total charge records: 20 View all charges

Deals & Funding of Piramal Pharma Limited

Piramal Pharma Limited has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025.

Total deals
10
Market trades
5
Funding rounds
3
Rights issue
1
Acquisition
1
Disclosed funding
₹4,300.42 Cr

Deals on record (5 of 10)

WhenDealAmountParties
Feb 2025Market trade₹150.77 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Oct 2023Market trade₹345.85 CrBuyer: East Bridge Capital Master Fund I Limited
Seller: an individual
Aug 2023Rights issue₹1,050 CrInvestors: Others - Piramal Pharma Limited, Icici Prudential Value Discovery Fund, 2 individuals
Jun 2023Market trade₹99.87 CrBuyer: The Vanguard Group Inc Ac Vanguard Total International Stock Index Fund
Seller: an individual
Nov 2022Market trade₹135.25 CrBuyer: an individual
Seller: Ishares Core Emerging Markets Mauritius Co
Premium access

Full deal history

All 10 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Piramal Pharma Limited

Piramal Pharma Limited has 11 MSME Form 1 returns on record between 2021 and 2024, listing 326 overdue payments to 94 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 94)

SupplierAmount dueDue sinceReported on
Refer Annexure••••••••••••
Scientific Research Instruments Company Private Limited••••••••••••
Sagra Hvac Private Limited••••••••••••
an individual supplier••••••••••••
Entex Private Limited••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 11 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Associated Brands with Piramal Pharma Limited

Piramal Pharma operates multiple associated brands including Piramal Pharma Solutions, Piramal Realty, and Piramal Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Piramal Pharma Solutions
Serves as a contract manufacturer of pharmaceutical products for industry partners.piramalpharmasolutions.com
Piramal Realty
Development services for residential, commercial, and mixed-use projects are provided.piramalrealty.com
Piramal Pharma
Innovative healthcare solutions are delivered through end-to-end manufacturing capabilities.piramalpharma.com
Piramal Group
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estatepiramal.com

Employees and EPFO Compliance at Piramal Pharma Limited

Piramal Pharma Limited has a workforce of 3,851 employees as of Apr 02, 2024.

Employee count
3,851
Active EPFO establishments
5
Employee growth
2.97%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Piramal Pharma Limited

Piramal Pharma has 1 subsidiary company and 2 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
2
Associated companies
Key Subsidiaries
Company NameCINShares Held
Piramal Pharma Ii Private LimitedU24230MH2022PTC384232-

Showing major subsidiaries. Total: 1.

CIN History of Piramal Pharma Limited

Piramal Pharma has one previous CIN (Corporate Identification Number): U24297MH2020PLC338592. The current CIN is L24297MH2020PLC338592, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24297MH2020PLC338592Current
U24297MH2020PLC338592Previous

News related to Piramal Pharma Limited

Recent Activity on Piramal Pharma Limited

Piramal Pharma Limited has 14 board changes on record since 2020: 12 appointments and 2 cessations. The latest: Amit Jain was appointed as Director on 14 May 2025.

AGM
Piramal Pharma Limited last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 300.00 Cr with Charge ID 101100712 was registered on 19 May 2025.
Appointed
Amit Jain was appointed as Director.
Ceased
Neeraj Bharadwaj ceased to be Director.
Filing
Piramal Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Appointed
Nathalie Ann Leitch was appointed as Director.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 100.00 Cr with Charge ID 101026540 was registered on 12 Dec 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 200.00 Cr with Charge ID 101019951 was registered on 10 Dec 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 100.00 Cr with Charge ID 101022133 was registered on 10 Dec 2024.
Charges
A charge with Others of Rs. 200.00 Cr registered on 23 Aug 2021 with Charge ID 100476536 was modified on 19 Sep 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 150.00 Cr with Charge ID 100977502 was registered on 10 Sep 2024.
Charges
A charge registered on 04 Jan 2022 via Charge ID 100528888 with Idbi Trusteeship Services Limited was fully satisfied on 06 May 2024.

33 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Piramal Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Piramal Pharma Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Piramal Pharma Limited

Piramal Pharma has 19 GST registrations: 19 active. The first 4 active GSTINs are listed below.

Total GSTINs
19
Active
19
GSTINStateStatusRegistered on
27AALCP0909M1Z1MaharashtraActive21 Jul 2020
27AALCP0909M2Z0MaharashtraActive28 Jul 2020
36AALCP0909M1Z2TelanganaActive21 Jul 2020
23AALCP0909M1Z9Madhya PradeshActive23 Jul 2020
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Piramal Pharma Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piramal Pharma Limited

Piramal Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 March 2020 (6+ years old) and is registered under CIN L24297MH2020PLC338592. Listed on BSE: 543635.

Piramal Pharma reported revenue of ₹8,869.08 Cr for FY 2025-26 (down 3.1% YoY) based on consolidated financials.

Piramal Pharma has 10 current directors:

The GSTIN of Piramal Pharma is 27AALCP0909M1Z1, registered in Maharashtra. The company has 19 GST registrations in all, of which 19 are active. Other active GSTINs include 27AALCP0909M2Z0 (Maharashtra), 36AALCP0909M1Z2 (Telangana), 23AALCP0909M1Z9 (Madhya Pradesh).

The CIN (Corporate Identification Number) of Piramal Pharma is L24297MH2020PLC338592. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Piramal Pharma is listed on BSE with code 543635.

Piramal Pharma has 55 court cases on record: 41 filed by the company and 10 filed against it. 32 are pending. Most are in the district courts.

Piramal Pharma was incorporated on 04 March 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.

Piramal Pharma has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025.

The peers of Piramal Pharma by revenue are Dow Chemical International Private Limited, Reckitt Benckiser (India) Private Limited, Gujarat State Fertilizers & Chemicals Limited, Divi's Laboratories Limited, Macleods Pharmaceuticals Ltd and 5 more, all in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Amit Jain was appointed as Director on 14 May 2025. Neeraj Bharadwaj ceased to be Director on 14 May 2025. Nathalie Ann Leitch was appointed as Director on 28 Jan 2025. Piramal Pharma has 14 board changes on record in total.

Piramal Pharma has 11 MSME Form 1 returns on record between 2021 and 2024, listing 326 overdue payments to 94 micro and small suppliers. The latest return was filed on 13 May 2024.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available